Latest News

According to a phase 2 trial, low-dose azacitidine plus venetoclax was found to be a feasible maintenance strategy for patients with acute myeloid leukemia following intensive and low-intensity induction.

Results from a phase 2 study found that ceralasertib plus olaparib was well tolerated and demonstrated promising clinical activity among patients with recurrent platinum-sensitive ovarian cancer, regardless of tumor genomic instability.

The U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel for adult patients with relapsed or refractory MCL who have received at least 2 prior lines of systemic therapy including a BTK inhibitor.

According to updated data presented at the 2024 ASCO Annual Meeting, lorlatinib has provided the longest progression-free survival ever reported among patients with advanced ALK-positive non-small cell lung cancer.

The phase 2 KEYVIBE-005 study found vibostolimab coformulated with pembrolizumab had durable antitumor activity and manageable safety among patients with advanced mismatch repair deficient (dMMR) endometrial cancer.

According to updated results from the INAVO120 trial, inavolisib plus palbociclib and fulvestrant sustained clinical benefit beyond disease progression among patients with PIK3A-mutated, HR-positive, HER2-negative, locally advanced or...

Decitabine and cedazuridine plus venetoclax demonstrated efficacy as a fully oral regimen and was found to be safe for older or unfit patients with acute myeloid leukemia, according to a phase 2 study.

According to results from a phase 2 trial, the combination of sintilimab with pegaspargase, gemcitabine, and oxaliplatin exhibits efficacy and safety as a frontline regimen among patients with advanced extranodal natural killer/T-cell...

According to final overall survival results from the MONARCH 3 study, abemaciclib plus a nonsteroidal aromatase inhibitor improved overall survival and prolonged progression-free survival among patients with HR-positive, HER2-negative...

According to results from the phase 2 RELATIVITY-060 study, the addition of relatlimab to nivolumab and chemotherapy did not improve objective response among patients with unresectable, locally advanced or metastatic gastric or...